Biocon Biologics CreditWatch Positive on Debt Reduction Plan
Filing Summary
Biocon Biologics, a subsidiary of Biocon Ltd, has been placed on CreditWatch with a positive outlook by S&P Global Ratings due to its accelerated debt reduction strategy. The company plans to acquire a 25% stake from minority investors, including Viatris Inc., through equity swaps and cash, funded by a fresh equity issuance of approximately INR 45 billion. This transaction is expected to significantly reduce Biocon’s adjusted debt from INR 248 billion to INR 120 billion by March 2026. The transaction is pending shareholder approval and is expected to conclude by March 2026.
Biocon Biologics Limited, a subsidiary of Biocon Ltd, has been placed on CreditWatch with a positive outlook by S&P Global Ratings. This follows the company’s announcement of an accelerated debt reduction plan. The plan involves acquiring a 25% stake held by minority investors in Biocon Biologics. The acquisition will be executed through an equity swap and cash arrangement, which includes swapping compulsorily convertible preference shares (CCPS) held by Viatris Inc. for equity shares and cash.
The financial strategy involves funding the cash consideration to Viatris entirely through a fresh equity issuance of approximately INR 45 billion. This move is expected to materially reduce Biocon’s adjusted debt from INR 248 billion as of March 2025 to about INR 120 billion by March 2026. The transaction will eliminate other debt-like instruments, such as optionally convertible debentures and redeemable nonconvertible debentures, primarily through the proceeds from the equity issuance.
Operationally, the transaction will restructure Biocon’s capital framework to include only senior secured notes, bilateral loans, and working capital borrowings. The company aims to complete the equity issuance and the associated transactions by March 2026, subject to shareholder approvals. The restructuring is designed to streamline Biocon’s financial obligations and enhance its capital structure.
The timeline for the transaction is set to conclude by March 31, 2026. The process involves several phases, including the equity issuance, the swap of shares with Viatris and other minority investors, and the repayment of existing debt instruments. The completion of these phases is contingent upon receiving necessary shareholder approvals and successfully raising the required equity capital.
The primary parties involved in this transaction include Biocon Ltd, its subsidiary Biocon Biologics, and minority investors such as Viatris Inc. The transaction also involves equity investors like Serum Institute and credit investors including Tata Capital and True North. Each party plays a specific role in the equity swap and debt reduction process, contributing to the overall restructuring strategy.
The market context for this transaction is significant as it aligns with Biocon’s strategy to consolidate its stake in Biocon Biologics, thereby enhancing its operational and financial flexibility. The reduction in debt and restructuring of the capital framework are expected to improve the company’s financial health, subject to the successful execution of the equity issuance and shareholder approvals.
Biocon Ltd is a global biopharmaceutical company focused on enhancing affordable access to complex therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets. Biocon is committed to innovation and expanding its pipeline of promising novel assets in immunotherapy.